Quick View: FDA Proposes Removal of Interchangeability Designation for Biosimilars
Pharmaceuticals / United States / Fri 19 Apr, 2024
Latest Development: In a significant shift in regulatory approach, the FDA is urging Congress to eliminate the interchangeability designation that has long differentiated biosimilars in the US market. This proposed legislative change is set to resolve the confusion stemming from a two-tier system that has inadvertently created misconceptions